Download PDF
Z Gastroenterol 2019; 57(09): 1048-1050
DOI: 10.1055/a-0986-3364
Editorial
© Georg Thieme Verlag KG Stuttgart · New York

Prof. Dr. med. Stefan Zeuzem

Kongresspräsident der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten 2019
Britta Siegmund
Further Information

Publication History

Publication Date:
16 September 2019 (online)

Also available at
    Permissions and Reprints

Es ist mir eine besondere Freude und Ehre, meinen Vorgänger für Leitlinien im DGVS-Vorstand und Kollegen, Herrn Professor Dr. Stefan Zeuzem, als diesjährigen Kongresspräsidenten der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten vorzustellen.

 

  • Literatur

  • 1 Zeuzem S, Franke A, Lee JH. et al. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996; 24: 1003-1009
    CrossrefPubMedGoogle Scholar
  • 2 Zeuzem S, Ruster B, Lee JH. et al. Evaluation of a reverse hybridization assay for genotyping of hepatitis C virus. J Hepatol 1995; 23: 654-661
    CrossrefPubMedGoogle Scholar
  • 3 Roth WK, Lee JH, Ruster B. et al. Quantification of hepatitis C virus RNA by RT-PCR in comparison to the branched DNA method. Z Gastroenterol 1998; 36: 5-11
    PubMedGoogle Scholar
  • 4 Zeuzem S, Lee JH, Franke A. et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-1156
    CrossrefPubMedGoogle Scholar
  • 5 Zeuzem S, Teuber G, Lee JH. et al. Risk factors for the transmission of hepatitis C. J Hepatol 1996; 24: 3-10
    PubMedGoogle Scholar
  • 6 Davis GL, Esteban-Mur R, Rustgi V. et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499
    CrossrefPubMedGoogle Scholar
  • 7 Poynard T, Marcellin P, Lee SS. et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432
    CrossrefPubMedGoogle Scholar
  • 8 Berg T, Sarrazin C, Herrmann E. et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-609
    CrossrefPubMedGoogle Scholar
  • 9 Hezode C, Forestier N, Dusheiko G. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850
    CrossrefPubMedGoogle Scholar
  • 10 Feld JJ, Jacobson IM, Hezode C. et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373: 2599-2607
    CrossrefPubMedGoogle Scholar
  • 11 Zeuzem S, Jacobson IM, Baykal T. et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614
    CrossrefPubMedGoogle Scholar
  • 12 Zeuzem S, Soriano V, Asselah T. et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-639
    CrossrefPubMedGoogle Scholar
  • 13 Lynen Jansen P, Preiss JC, Muche-Borowski C. et al. The guidelines program of the DGVS. Z Gastroenterol 2013; 51: 643-650
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Lynen Jansen P, Siegmund B, Nothacker M. et al. Das Leitlinienprogramm der DGVS 2017. Z Gastroenterol 2017; 55: 39-49
    Article in Thieme ConnectPubMedGoogle Scholar